The article mentions that Revance Therapeutics has received 5 bullish analyst ratings in the last quarter, with an average price target of $41.8, which is higher than the current price of $32.115. This indicates a potential upside for the stock in the short term. The average price target has also increased by 9.05% from the previous average, which further supports the bullish sentiment.